Drug Therapy Cuts Risk of Breast Cancer Relapse

New drug combos delay tumor growth in advanced cases

(NEWSER) - Two new studies mark what could be the biggest breakthrough in treating breast cancer in more than a decade, researchers say. Both involve combining drug therapies that attack tumors in different ways, significantly delaying the time until women with advanced breast cancer became sicker, the AP reports. One treatment held tumor growth at bay for around six months longer than conventional treatments; the other delayed it for four months longer. More»

Sticking to advised limits would prevent thousands of cases

(NEWSER) - Drinking leads to at least 13,000 cases of cancer in Britain each year, a study finds—and thousands could be avoided if people would stick to alcohol guidelines. That UK-centric finding comes from a study that examined the tie between diet and cancer in eight European countries. Researchers discovered that among men, more than half of the cases of cancer of the upper digestive tract, colorectum, and liver attributed to alcohol in 2008 resulted from having more than two drinks daily; in women, more than 80% resulted from having more than one drink per day, the Guardian reports. More»

Natural drug discovery on the decline

(NEWSER) - Halaven, the new breast cancer drug the FDA approved in November, has an origin that’s rare in today’s pharmaceutical industry: It’s natural. Halaven is derived from halichondrin B, a chemical found in a species of black sponge that lives off the coast of Japan, the Wall Street Journal reports. Once that wouldn’t have been so remarkable, but lately large pharmaceutical companies have focused almost entirely on synthetic, targeted drugs. More»

Breast cancer, ovarian cancer, melanoma yield to new approaches

(NEWSER) - New treatments for cancer—breast, ovarian, and skin—raised hopes at this weekend's meeting of the American Society of Clinical Oncology in Chicago. The findings aren't enough for Robert Langreth of Forbes , who sees "serious questions about whether big drug companies may be rushing too fast." Judge for yourself.

• A single dose of radiation administered at the site of tumor removal deterred recurrence of breast cancer as well as the standard grueling course of radiation on the entire breast, the Chicago Tribune reports.

New report focuses on disparities in funding, incidence, survival

(NEWSER) - The number of women diagnosed with lung cancer is soaring, but federal funding for research lags even though the disease is more common than cancer of the breast, prostate, and colon—combined. A new report drills down on research about women and lung cancer, sorting out findings about incidence, gender disparities, and survival. Perhaps most interesting, "all federal spending for lung cancer research amounts to $1,249 for each lung cancer death," Richard Know writes for NPR . "Spending for breast cancer research is 21 times higher—$27,480 per death." More»